{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:44:26Z","timestamp":1788813866419,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>In clinically node-positive breast cancer patients receiving neoadjuvant systemic therapy (NST), nodal metastases can be initially marked and then removed during surgical axillary staging. Marking methods vary significantly in terms of feasibility and cost. The purpose of the extended TATTOO trial was to report on the false-negative rate (FNR) of the low-cost method carbon tattooing.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The international prospective single-arm TATTOO trial included clinically node-positive breast cancer patients planned for NST from November 2017 to January 2021. For the present analysis, patients who received both the targeted procedure with or without an additional sentinel lymph node (SLN) biopsy <jats:italic>and<\/jats:italic> a completion axillary lymph node dissection (ALND) were selected. Primary endpoint was the FNR.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Out of 172 included patients, 149 had undergone a completion ALND. The detection rate for the tattooed node was 94.6% (141 out of 149). SLN biopsy was attempted in 132 out of 149 patients with a detection rate of 91.7% (121 out of 132). SLN and tattooed node were identical in 58 out of 121 individuals (47.9%). The combined procedure, i.e. targeted axillary dissection (TAD) was successful in 147 of 149 cases (98.7%). Four out of 65 patients with a clinically node-negative status after NST had a negative TAD but metastases on ALND, corresponding to a FNR of 6.2%. All false-negative TAD procedures were performed in the first 2\u00a0years of the trial (2018\u20132019, <jats:italic>p<\/jats:italic>\u2009=\u20090.022).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Carbon tattooing is a feasible marking method for TAD with a high detection rate and an acceptably low FNR.<\/jats:p>\n                <jats:p>The TATTOO trial was preregistered as prospective trial before initiation at the University of Rostock, Germany (DRKS00013169).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10549-022-06588-2","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T06:03:10Z","timestamp":1650607390000},"page":"589-595","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["False-negative rate in the extended prospective TATTOO trial evaluating targeted axillary dissection by carbon tattooing in clinically node-positive breast cancer patients receiving neoadjuvant systemic therapy"],"prefix":"10.1007","volume":"193","clinical-trial-number":[{"clinical-trial-number":"drks00013169","registry":"10.18810\/drks"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9518-0902","authenticated-orcid":false,"given":"Jana","family":"de Boniface","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Frisell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"K\u00fchn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Wiklander-Br\u00e5kenhielm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Dembrower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Nyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Zouzos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toralf","family":"Reimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffi","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,22]]},"reference":[{"issue":"6","key":"6588_CR1","doi-asserted-by":"publisher","first-page":"e210891","DOI":"10.1001\/jamasurg.2021.0891","volume":"156","author":"S Samiei","year":"2021","unstructured":"Samiei S, Simons JM, Engelen SME, Beets-Tan RGH, Classe JM, Smidt ML, Group E (2021) Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease: a systematic review and meta-analysis. JAMA Surg 156(6):e210891. https:\/\/doi.org\/10.1001\/jamasurg.2021.0891","journal-title":"JAMA Surg"},{"key":"6588_CR2","doi-asserted-by":"crossref","unstructured":"Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Blair SL (2021) NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. In., Version 3.2021 edn: nccn.org","DOI":"10.6004\/jnccn.2021.0023"},{"issue":"10","key":"6588_CR3","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","volume":"32","author":"HJ Burstein","year":"2021","unstructured":"Burstein HJ, Curigliano G, Thurlimann B, Weber WP, Poortmans P, Regan MM, Senn HJ, Winer EP, Gnant M, Panelists of the St Gallen Consensus C (2021) Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol 32(10):1216\u20131235. https:\/\/doi.org\/10.1016\/j.annonc.2021.06.023","journal-title":"Ann Oncol"},{"issue":"3","key":"6588_CR4","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/SLA.0000000000003075","volume":"269","author":"JM Simons","year":"2019","unstructured":"Simons JM, van Nijnatten TJA, van der Pol CC, Luiten EJT, Koppert LB, Smidt ML (2019) Diagnostic accuracy of different surgical procedures for axillary staging after neoadjuvant systemic therapy in node-positive breast cancer: a systematic review and meta-analysis. Ann Surg 269(3):432\u2013442. https:\/\/doi.org\/10.1097\/SLA.0000000000003075","journal-title":"Ann Surg"},{"key":"6588_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071539","author":"PK Swarnkar","year":"2021","unstructured":"Swarnkar PK, Tayeh S, Michell MJ, Mokbel K (2021) The evolving role of marked lymph node biopsy (MLNB) and targeted axillary dissection (TAD) after neoadjuvant chemotherapy (NACT) for node-positive breast cancer: systematic review and pooled analysis. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13071539","journal-title":"Cancers (Basel)"},{"issue":"4","key":"6588_CR6","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.ejso.2020.10.014","volume":"47","author":"S Kahler-Ribeiro-Fontana","year":"2021","unstructured":"Kahler-Ribeiro-Fontana S, Pagan E, Magnoni F, Vicini E, Morigi C, Corso G, Intra M, Canegallo F, Ratini S, Leonardi MC et al (2021) Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up. Eur J Surg Oncol 47(4):804\u2013812. https:\/\/doi.org\/10.1016\/j.ejso.2020.10.014","journal-title":"Eur J Surg Oncol"},{"key":"6588_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071565","author":"M Banys-Paluchowski","year":"2021","unstructured":"Banys-Paluchowski M, Gasparri ML, de Boniface J, Gentilini O, Stickeler E, Hartmann S, Thill M, Rubio IT, Di Micco R, Bonci EA et al (2021) Surgical management of the axilla in clinically node-positive breast cancer patients converting to clinical node negativity through neoadjuvant chemotherapy: current status, knowledge gaps, and rationale for the EUBREAST-03 AXSANA study. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13071565","journal-title":"Cancers (Basel)"},{"issue":"5","key":"6588_CR8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.clbc.2017.04.006","volume":"17","author":"TJA van Nijnatten","year":"2017","unstructured":"van Nijnatten TJA, Simons JM, Smidt ML, van der Pol CC, van Diest PJ, Jager A, van Klaveren D, Kam BLR, Lobbes MBI, de Boer M et al (2017) A novel less-invasive approach for axillary staging after neoadjuvant chemotherapy in patients with axillary node-positive breast cancer by combining radioactive iodine seed localization in the axilla with the sentinel node procedure (RISAS): a Dutch prospective multicenter validation study. Clin Breast Cancer 17(5):399\u2013402. https:\/\/doi.org\/10.1016\/j.clbc.2017.04.006","journal-title":"Clin Breast Cancer"},{"issue":"6","key":"6588_CR9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/tbj.14232","volume":"27","author":"M Powell","year":"2021","unstructured":"Powell M, Gate T, Kalake O, Ranjith C, Pennick MO (2021) Magnetic seed localization (magseed) for excision of impalpable breast lesions-the north wales experience. Breast J 27(6):529\u2013536. https:\/\/doi.org\/10.1111\/tbj.14232","journal-title":"Breast J"},{"issue":"9","key":"6588_CR10","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/j.ejso.2018.05.035","volume":"44","author":"S Hartmann","year":"2018","unstructured":"Hartmann S, Reimer T, Gerber B, Stubert J, Stengel B, Stachs A (2018) Wire localization of clip-marked axillary lymph nodes in breast cancer patients treated with primary systemic therapy. Eur J Surg Oncol 44(9):1307\u20131311. https:\/\/doi.org\/10.1016\/j.ejso.2018.05.035","journal-title":"Eur J Surg Oncol"},{"key":"6588_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000004572","author":"S Kuemmel","year":"2020","unstructured":"Kuemmel S, Heil J, Rueland A, Seiberling C, Harrach H, Schindowski D, Lubitz J, Hellerhoff K, Ankel C, Grasshoff ST et al (2020) A prospective, multicenter registry study to evaluate the clinical feasibility of targeted axillary dissection (TAD) in node-positive breast cancer patients. Ann Surg. https:\/\/doi.org\/10.1097\/SLA.0000000000004572","journal-title":"Ann Surg"},{"issue":"10","key":"6588_CR12","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1055\/a-1471-4234","volume":"81","author":"S Hartmann","year":"2021","unstructured":"Hartmann S, Stachs A, Kuhn T, de Boniface J, Banys-Paluchowski M, Reimer T (2021) Targeted removal of axillary lymph nodes after carbon marking in patients with breast cancer treated with primary chemotherapy. Geburtshilfe Frauenheilkd 81(10):1121\u20131127. https:\/\/doi.org\/10.1055\/a-1471-4234","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"3","key":"6588_CR13","doi-asserted-by":"publisher","first-page":"801","DOI":"10.4143\/crt.2017.210","volume":"50","author":"S Park","year":"2018","unstructured":"Park S, Koo JS, Kim GM, Sohn J, Kim SI, Cho YU, Park BW, Park VY, Yoon JH, Moon HJ et al (2018) Feasibility of charcoal tattooing of cytology-proven metastatic axillary lymph node at diagnosis and sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patients. Cancer Res Treat 50(3):801\u2013812. https:\/\/doi.org\/10.4143\/crt.2017.210","journal-title":"Cancer Res Treat"},{"issue":"3","key":"6588_CR14","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.clbc.2019.01.013","volume":"19","author":"I Natsiopoulos","year":"2019","unstructured":"Natsiopoulos I, Intzes S, Liappis T, Zarampoukas K, Zarampoukas T, Zacharopoulou V, Papazisis K (2019) Axillary lymph node tattooing and targeted axillary dissection in breast cancer patients who presented as cn+ before neoadjuvant chemotherapy and became cN0 after treatment. Clin Breast Cancer 19(3):208\u2013215. https:\/\/doi.org\/10.1016\/j.clbc.2019.01.013","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"6588_CR15","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s10549-020-05961-3","volume":"185","author":"A Goyal","year":"2021","unstructured":"Goyal A, Puri S, Marshall A, Valassiadou K, Hoosein MM, Carmichael AR, Erdelyi G, Sharma N, Dunn J, York J (2021) A multicentre prospective feasibility study of carbon dye tattooing of biopsied axillary node and surgical localisation in breast cancer patients. Breast Cancer Res Treat 185(2):433\u2013440. https:\/\/doi.org\/10.1007\/s10549-020-05961-3","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"6588_CR16","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1245\/s10434-019-07419-3","volume":"26","author":"R Patel","year":"2019","unstructured":"Patel R, MacKerricher W, Tsai J, Choy N, Lipson J, Ikeda D, Pal S, De Martini W, Allison KH, Wapnir IL (2019) Pretreatment tattoo marking of suspicious axillary lymph nodes: reliability and correlation with sentinel lymph node. Ann Surg Oncol 26(8):2452\u20132458. https:\/\/doi.org\/10.1245\/s10434-019-07419-3","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"6588_CR17","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.ejso.2019.11.501","volume":"46","author":"TM Allweis","year":"2020","unstructured":"Allweis TM, Menes T, Rotbart N, Rapson Y, Cernik H, Bokov I, Diment J, Magen A, Golan O, Levi-Bendet N et al (2020) Ultrasound guided tattooing of axillary lymph nodes in breast cancer patients prior to neoadjuvant therapy, and identification of tattooed nodes at the time of surgery. Eur J Surg Oncol 46(6):1041\u20131045. https:\/\/doi.org\/10.1016\/j.ejso.2019.11.501","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"6588_CR18","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1093\/bjs\/znaa083","volume":"108","author":"S Hartmann","year":"2021","unstructured":"Hartmann S, Kuhn T, de Boniface J, Stachs A, Winckelmann A, Frisell J, Wiklander-Brakenhielm I, Stubert J, Gerber B, Reimer T (2021) Carbon tattooing for targeted lymph node biopsy after primary systemic therapy in breast cancer: prospective multicentre TATTOO trial. Br J Surg 108(3):302\u2013307. https:\/\/doi.org\/10.1093\/bjs\/znaa083","journal-title":"Br J Surg"},{"issue":"12","key":"6588_CR19","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1002\/cncr.25066","volume":"116","author":"AS Brown","year":"2010","unstructured":"Brown AS, Hunt KK, Shen J, Huo L, Babiera GV, Ross MI, Meric-Bernstam F, Feig BW, Kuerer HM, Boughey JC et al (2010) Histologic changes associated with false-negative sentinel lymph nodes after preoperative chemotherapy in patients with confirmed lymph node-positive breast cancer before treatment. Cancer 116(12):2878\u20132883. https:\/\/doi.org\/10.1002\/cncr.25066","journal-title":"Cancer"},{"issue":"22","key":"6588_CR20","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB et al (2017) Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 376(22):2147\u20132159. https:\/\/doi.org\/10.1056\/NEJMoa1612645","journal-title":"N Engl J Med"},{"issue":"7","key":"6588_CR21","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A et al (2019) Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 380(7):617\u2013628. https:\/\/doi.org\/10.1056\/NEJMoa1814017","journal-title":"N Engl J Med"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06588-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-022-06588-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06588-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T13:18:17Z","timestamp":1652793497000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-022-06588-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,22]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["6588"],"URL":"https:\/\/doi.org\/10.1007\/s10549-022-06588-2","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,22]]},"assertion":[{"value":"4 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have not disclosed any competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}